Comparison tool
Lanreotide vs Pegvisomant side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Lanreotide | Pegvisomant |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | Somatuline, Somatuline Depot, Autogel | Somavert |
| FDA approved | Yes | Yes |
| Clinical status | FDA Approved - Acromegaly, GEP-NETs, and carcinoid syndrome
| FDA approved for acromegaly
|
| What to expect | Acromegaly, neuroendocrine tumors, hormone control | Acromegaly, GH blockade, IGF-1 normalization |
| How it works | Lanreotide is described as a somatostatin analog with strongest receptor preference for SSTR2 and SSTR5 and weaker binding across SSTR1, SSTR3, and SSTR4. The source links SSTR2/SSTR5 activity in pituitary cells to reduced growth hormone release and lower IGF-1. In neuroendocrine tumor contexts, the evidence reports both reduced hormone over-secretion and direct growth-slowing activity. The long-acting gel depot is described as releasing the peptide gradually, supporting an approximately four-week interval. | Pegvisomant is described as a PEGylated, genetically modified human growth hormone analog that functions as a growth hormone receptor antagonist. It can bind receptor sites without allowing the receptor complex to signal normally, which reduces downstream IGF-1 production. The source also notes that this receptor-level action does not directly lower pituitary growth hormone output or shrink a pituitary tumor, so growth hormone laboratory values and imaging follow-up may need separate interpretation. |
| Typical dosing | 60-120 mg every 4 weeks · Every 4 weeks (deep SC) | 10-30 mg daily · Once daily · Subcutaneous injection daily |
| Research dosing | 60-120 mg deep SC every 4 weeks · Long-term / chronic use · Deep subcutaneous injection | 40 mg loading dose · Long-term / chronic use · Subcutaneous injection daily |
| Typical duration | Long-term / chronic use | Long-term / chronic use |
| Administration | Deep subcutaneous injection | Subcutaneous injection daily |
| Timing | Morning or as directed With or without food | Morning or as directed With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+4 more
|
+3 more
|
| Research summary | The source describes a mature clinical evidence base. It highlights the CLARINET phase 3 trial in more than 200 patients with metastatic grade 1 or 2 enteropancreatic neuroendocrine tumors, reporting a 53 percent reduction in risk of progression or death and progression-free survival that was not reached, compared with about 18 months for placebo. For acromegaly, the supplied summary says multicenter studies found IGF-1 normalization and growth hormone reductions in a substantial share of patients, with results characterized as comparable to octreotide. The same source notes class-like adverse effects including diarrhea, gallstones, and injection-site reactions. | The source describes Pegvisomant as having randomized human trial evidence, including a 12-week New England Journal of Medicine study by Trainer and colleagues in 2000 that reported dose-related IGF-1 reductions and higher normalization at the top studied dose than placebo. It also cites longer-term observational experience and ACROSTUDY surveillance as supporting IGF-1 control in many adequately dosed patients. Key uncertainties and monitoring issues noted by the source include liver enzyme elevations and the fact that receptor blockade does not itself manage tumor size. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.